These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9123921)

  • 1. Current research on the immunomodulatory effect of allogeneic blood transfusion.
    Dzik S; Blajchman MA; Blumberg N; Kirkley SA; Heal JM; Wood K
    Vox Sang; 1996; 70(4):187-94. PubMed ID: 9123921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness.
    Roelen DL; Dover EL; Niimi M; Young NT; Morris PJ; Wood KJ
    Eur J Immunol; 1996 Jul; 26(7):1468-74. PubMed ID: 8766548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms.
    Blajchman MA
    Vox Sang; 1998; 74 Suppl 2():315-9. PubMed ID: 9704462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.
    Clark DA; Gorczynski RM; Blajchman MA
    Transfusion; 2008 May; 48(5):814-21. PubMed ID: 18298594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of donor-specific T cell anergy by portal venous injection of allogeneic cells.
    Sugiura K; Kato K; Hashimoto F; Jin T; Amoh Y; Yamamoto Y; Morita H; Okumura K; Ikehara S
    Immunobiology; 1997 Nov; 197(5):460-77. PubMed ID: 9413746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of hyporesponsiveness caused by donor-specific transfusion to allogeneic minor antigens.
    Nomoto K; Kanoh K; Suzuki H; Shimura T; Kuwano H
    Eur Surg Res; 2001; 33(3):217-24. PubMed ID: 11490125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion-induced immunomodulation and its clinical consequences.
    Blumberg N; Triulzi DJ; Heal JM
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):24-35. PubMed ID: 2134638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological aspects of blood transfusions.
    Brand A
    Transpl Immunol; 2002 Aug; 10(2-3):183-90. PubMed ID: 12216948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of acquired thymic tolerance: induction of transplant tolerance by adoptive transfer of in vivo allomhc peptide activated syngeneic T cells.
    Ali A; Garrovillo M; Oluwole OO; Depaz HA; Gopinathan R; Engelstad K; Hardy MA; Oluwole SF
    Transplantation; 2001 May; 71(10):1442-8. PubMed ID: 11391233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood transfusion and organ transplantation.
    Ross WB; Yap PL
    Blood Rev; 1990 Dec; 4(4):252-8. PubMed ID: 2076472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretransplant blood transfusion without additional immunotherapy generates CD25+CD4+ regulatory T cells: a potential explanation for the blood-transfusion effect.
    Bushell A; Karim M; Kingsley CI; Wood KJ
    Transplantation; 2003 Aug; 76(3):449-55. PubMed ID: 12923427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood transfusion and constituent transfusion.
    Brand A; Lagaaij EL
    Curr Opin Immunol; 1989 Aug; 1(6):1184-90. PubMed ID: 2529878
    [No Abstract]   [Full Text] [Related]  

  • 15. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells.
    Blajchman MA; Bardossy L; Carmen R; Sastry A; Singal DP
    Blood; 1993 Apr; 81(7):1880-2. PubMed ID: 8461473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble and cell-associated forms of some yet to be identified factor in transfused blood which promotes solid tumor growth in mice.
    Okuyama M; Motoyama S; Saito S; Saito R; Nakamura M; Imano H; Minamiya Y; Ogawa J
    Surg Today; 2004; 34(8):673-7. PubMed ID: 15290397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of unresponsiveness to skin allografts in adult mice disparate at defined regions of the H-2 complex. II. Effect of pre-graft donor-specific blood transfusions in ALS-treated mice.
    Wood ML; Monaco AP
    Transplantation; 1984 Jan; 37(1):39-42. PubMed ID: 6364487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD45RC+ CD4 T cell subsets are maintained in an unresponsive state by the persistence of transfusion-derived alloantigen.
    Yang CP; McDonagh M; Bell EB
    Transplantation; 1995 Jul; 60(2):192-9. PubMed ID: 7624962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic aspects of the blood transfusion effect.
    Peugh WN; Wood KJ; Morris PJ
    Transplantation; 1988 Sep; 46(3):438-43. PubMed ID: 3047933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive transfusion of ex vivo donor alloantigen-stimulated CD4(+)CD25(+) regulatory T cells ameliorates rejection of DA-to-Lewis rat liver transplantation.
    Pu LY; Wang XH; Zhang F; Li XC; Yao AH; Yu Y; Lv L; Li GQ
    Surgery; 2007 Jul; 142(1):67-73. PubMed ID: 17630002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.